Observational studyBMC neurology2022

Real-world effectiveness and safety of fingolimod in patients with multiple sclerosis in the Czech Republic: results from core and extension parts of the GOLEMS study up to 48 months.

Veronika Tichá et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.